Public Employees Retirement System of Ohio Raises Position in 10x Genomics $TXG

Key Points

• The Public Employees Retirement System of Ohio increased its holdings in 10x Genomics (NASDAQ:TXG) by 210.1% in Q2, now owning 100,636 shares valued at $1,165,000.
• 10x Genomics reported a surprise profit with earnings per share of $0.28, exceeding analyst expectations of a loss, and revenue of $172.91 million, which was also above estimates.
• Various analysts have set new price targets for 10x Genomics, ranging from $13.00 to $16.00, while the stock currently has a consensus rating of "Hold" and an average target price of $13.65.

Public Employees Retirement System of Ohio increased its holdings in 10x Genomics (NASDAQ:TXG - Free Report) by 210.1% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 100,636 shares of the company's stock after purchasing an additional 68,182 shares during the quarter. Public Employees Retirement System of Ohio owned 0.08% of 10x Genomics worth $1,165,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in the business. Ballentine Partners LLC bought a new stake in 10x Genomics in the 2nd quarter worth $180,000. Counterpoint Mutual Funds LLC bought a new stake in 10x Genomics during the second quarter worth about $906,000. Diversified Trust Co raised its holdings in 10x Genomics by 16.6% in the second quarter. Diversified Trust Co now owns 66,741 shares of the company's stock worth $773,000 after buying an additional 9,505 shares during the last quarter. Wealth Enhancement Advisory Services LLC raised its holdings in 10x Genomics by 209.1% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 96,001 shares of the company's stock worth $1,112,000 after buying an additional 64,940 shares during the last quarter. Finally, Pallas Capital Advisors LLC raised its holdings in 10x Genomics by 138.8% in the second quarter. Pallas Capital Advisors LLC now owns 56,776 shares of the company's stock worth $657,000 after buying an additional 32,996 shares during the last quarter. Hedge funds and other institutional investors own 84.68% of the company's stock.

10x Genomics Trading Up 3.6%

TXG opened at $12.75 on Friday. The firm has a market capitalization of $1.59 billion, a PE ratio of -18.21 and a beta of 2.05. The firm has a 50 day moving average of $13.17 and a two-hundred day moving average of $11.00. 10x Genomics has a 12-month low of $6.78 and a 12-month high of $20.92.

10x Genomics (NASDAQ:TXG - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.63. The firm had revenue of $172.91 million during the quarter, compared to analyst estimates of $139.36 million. 10x Genomics had a negative net margin of 13.13% and a negative return on equity of 12.88%. The business's quarterly revenue was up 12.9% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.32) EPS. 10x Genomics has set its Q3 2025 guidance at EPS. As a group, analysts predict that 10x Genomics will post -1.43 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently weighed in on TXG shares. UBS Group boosted their price objective on shares of 10x Genomics from $12.00 to $13.00 and gave the company a "neutral" rating in a report on Friday, August 8th. Deutsche Bank Aktiengesellschaft set a $14.00 target price on shares of 10x Genomics and gave the stock a "hold" rating in a research report on Friday, August 8th. Bank of America lifted their price objective on shares of 10x Genomics from $12.00 to $13.00 and gave the stock a "neutral" rating in a research note on Thursday, June 26th. Canaccord Genuity Group set a $16.00 price target on 10x Genomics in a research report on Monday, August 11th. Finally, Morgan Stanley decreased their price objective on shares of 10x Genomics from $18.00 to $17.00 and set an "overweight" rating for the company in a research note on Tuesday, August 12th. Six research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $13.65.

Insider Activity at 10x Genomics

In other 10x Genomics news, insider Benjamin J. Hindson sold 7,486 shares of 10x Genomics stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $13.79, for a total transaction of $103,231.94. Following the sale, the insider owned 440,888 shares of the company's stock, valued at $6,079,845.52. The trade was a 1.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Serge Saxonov sold 9,348 shares of 10x Genomics stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $13.79, for a total transaction of $128,908.92. Following the sale, the chief executive officer directly owned 945,892 shares in the company, valued at approximately $13,043,850.68. This trade represents a 0.98% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 39,149 shares of company stock valued at $539,865. 9.39% of the stock is owned by company insiders.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.

Want to see what other hedge funds are holding TXG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for 10x Genomics (NASDAQ:TXG - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.